echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Commun: Chromatin accessability of circulating CD8-T cells predicts the response of gastric cancer patients to PD-1 therapy

    Nat Commun: Chromatin accessability of circulating CD8-T cells predicts the response of gastric cancer patients to PD-1 therapy

    • Last Update: 2021-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Studies of immune cell failure and tumor-soaked lymphocyte (TIL) dysfunction caused by persistent antigen stimuli such as chronic viral infections and tumors have shown that cell surface proteins are associated with impaired immune cell function.
    These proteins include multiple co-inhibitors or checkpoint subjects such as CTLA-4 (cytotoxic T lymphocyte antigen 4, CD152), PD-1 (programmed death subject 1, CD279), TIM-3 (T-cell immunoglobulin adhesive protein-3) and LAG-3 (lymphocyte active gene 3).
    , clinical trials have been conducted using meso-antibodies (Abs) for immunosuppressant ICI to restore T-cell function.
    these ICI drugs have now been approved for patients with metastatic stomach cancer (mGC) who have failed at least two systematic chemotherapy treatments.
    although tumor genomic analysis has identified a small percentage of patients with stomach cancer (GC) who could benefit from anti-PD-1 treatment, not all reactions can be explained by tumor sequencing alone.
    The molecular diagnostic schematic based on ATAC-seq explores the obitakous genetic factors associated with the response to differences in anti-PD-1 therapy by quantitatively assessing the accessability of whole genome chromatin to circulating CD8-T cells in the patient's outer blood.
    Through atTIC-seq (a targeted open chromatin research method combined with high-volume sequencing techniques), the researchers identified a unique open area of chromatin that can distinguish between respondents and non-responders of anti-PD-1 therapy.
    in the respondent group, GC patients with high chromatin openness of circulating CD8-T cells were significantly more developed.
    correspondingly, patients with high chromosomal openness at specific genomic locations of circulating CD8-T cells had a significantly higher survival rate than those with chromosomal closure.
    the correlation between
    circulating CD8-T cell chromatin openness and anti-PD-1 therapy response, the study revealed that the ode genetic characteristics of baseline CD8-T cells could be used to identify metastasis GC patients who could potentially benefit from anti-PD-1 therapy.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.